CiteFacts · FDA Drug Shortages · FDA source
Morphine Sulfate Injection
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. | Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1) | Available | 08/18/2026 |
| Fresenius Kabi USA, LLC | Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11) | Unavailable | 08/04/2026 |
| Fresenius Kabi USA, LLC | Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11) | Unavailable | 08/04/2026 |
| Fresenius Kabi USA, LLC | Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01) | Unavailable | 08/04/2026 |
| Hikma Pharmaceuticals USA, Inc. | Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10) | Available | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10) | Available | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01) | Available | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01) | Available | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25) | Available | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25) | Available | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25) | Available | 08/13/2026 |
| Hospira, Inc., a Pfizer Company | Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01) | Unavailable | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05) | Unavailable | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20) | Unavailable | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01) | Unavailable | 08/07/2026 |
| Piramal Critical Care Inc. | Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02) | Limited Availability | 08/04/2026 |
| Piramal Critical Care Inc. | Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02) | Available | 08/04/2026 |
Source facts
Grouped generic ingredient: Morphine Sulfate Injection · 24 package records · Latest FDA row update: 08/18/2026
Therapeutic categories: Analgesia/Addiction
Dosage forms: Injection
Routes: EPIDURAL, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.